Hirsch F W, Kraaz B, Löhr G W, Bross K J
Onkologische Abteilung der Medizinischen Universitätsklinik, Freiburg.
Onkologie. 1988 Dec;11(6):263-5. doi: 10.1159/000216552.
Eighteen patients with advanced renal cell carcinoma were treated with recombinant interferon alpha-2a (18 million IU s.c. three times a week). 9 patients had received prior hormonal therapy (tamoxifen). On entering the therapeutic schedule with recombinant interferon alpha-2a, all patients had progressive disease with multiple metastases. Flu-like symptoms occurred in general; they were severe in 9 cases. An impairment of the liver was shown by a rise of SGOT/SGPT and alkaline phosphatase in 2 patients, the gamma-GT was raised in 7 patients. The kidney function worsened in 3 cases. A fall in blood cell counts was seen in 8 cases. Five patients developed a transient stomatitis. Five patients (5/18) showed stable disease with the longest response duration of 17 months. One patient showed a complete remission 5 months after starting therapy for a duration of 7 months until now. Both the limited benefit from this treatment as well as some severe side effects indicate the need for further special evaluation and possible improvements of this therapeutic approach.
18例晚期肾细胞癌患者接受重组干扰素α-2a治疗（皮下注射1800万国际单位，每周3次）。9例患者先前接受过激素治疗（他莫昔芬）。开始使用重组干扰素α-2a治疗时，所有患者均有进展性疾病且伴有多处转移。一般会出现流感样症状；9例症状严重。2例患者的谷草转氨酶/谷丙转氨酶和碱性磷酸酶升高表明肝脏受损，7例患者的γ-谷氨酰转肽酶升高。3例患者肾功能恶化。8例患者血细胞计数下降。5例患者出现短暂性口腔炎。5例患者（5/18）病情稳定，最长缓解持续时间为17个月。1例患者在开始治疗5个月后出现完全缓解，至今持续7个月。这种治疗的益处有限以及一些严重的副作用表明需要对此治疗方法进行进一步的专门评估和可能的改进。
